

## REFERENCES

1. Glassoch RJ. Therapy of idiopathic nephritic syndrome in adults. *Am J Nephrol* 1993; 13:422-8
2. Beaufils H, Alphonse JC, Guedon J, Legaain M. Focal glomerulosclerosis : Natural history and treatment. *Nephron* 1978; 21:75-85
3. Cameron JS, Turner Dr, Ogg CS, Chantler C, Williams DG. The long-term prognosis of patients with focal segmental glomerulosclerosis. *Clin Nephron* 1978; 10:213-8
4. Baldwin DS. Chronic glomerulonephritis : non immunologic mechanism of progressive glomerular damage. *Kidney Int* 1982; 21:109-20
5. *Nephrology News and Issues America* 1995; 4:8-10

6. ประสิทธิ์ พุตุระกุล และคณะ. โรคไตในกุมารเวชศาสตร์ : แนวคิดที่เลือกสรร.  
ใน วิลโล ซินธเนศ, อุษา ทิสยากร, อนันต์ ศรีเกียรติขจร,  
วงศ์วรรณ วงศ์สุภา, สุทธิวรรณ ปรีชา (eds). Proceedings of the  
Medical Congress in Commemorations of the 50<sup>th</sup>  
Anniversary of the Faculty of Medicine, Chulalongkorn  
University. โรงพิมพ์จุฬาลงกรณ์มหาวิทยาลัย, กรุงเทพฯ 2540  
หน้า 261-78
7. Dixon FJ. Glomerulonephritis and Immunopathology.  
Hosp Practice 1967, Nov pp 35-43
8. Chase WH. The pathogenesis of glomerulonephritis : Review of  
three types of experimental nephritis. Canal Med Assoc J  
1967; 97:852
9. Cochrane CG. Immune complex and complement in tissue  
injury. J Allergy 1968; 42:113
10. Daniel V, Trautmann Y, Konrod M, Nayir A, Scharen K.  
T-lymphocyte populations, cytokines and other growth  
factors in serum and urine of children with idiopathic  
nephritic syndrome. Clin Nephrol 1997; 47:289-97

11. Balow JE, Austin HA. Renal disease in systemic lupus erythematosus. *Rheum Dis Clin North Am* 1988; 14:117-33
12. Golbus J, McCune WJ. Lupus nephritis. Classification, prognosis immunopathogenesis and treatment. *Rheum Dis Clin North Am* 1994; 20:217-42
13. Chatenond L, Bach M-A. Abnormalities of T-cell subsets in glomerulonephritis and systemic lupus erythematosus. *Kidney Int* 1991; 20:313-6
14. Futrakul N, Butthep P, Patumraj S, Tipprukmas N, Futrakul P. Enhanced tumor necrosis factor in the serum and renal hypoperfusion in nephrosis associated with focal segmental glomerulosclerosis. *Ren Fail* 2000; 22:213-7
15. Kaysen GA. Hyperlipidemia of the nephritic syndrome. *Kidney Int* 1991; 39 (suppl 31):S8—S15
16. Moorhead JF. Lipid and progressive kidney disease. *Kidney Int* 1991; 39 (suppl 31):S31—S40
17. Keane WF, Kasiske BL, O'Donnell MP. Lipidane progressive glomerulosclerosis. *Am J Nephrol* 1988; 8:261-71

18. Nath KA. Reactive oxygen species in renal disease.  
in: Andreucci VE, Fine LG (eds). *Intranational Year Book of Nephrology*. Dordrecht Kluwer 1991, pp 47-61
19. Nath KA, Salahudeen AK, Shah SV. Cellular and biochemical mechanisms in progressive renal disease. *Curr Nephrol* 1993; 16:221-56
20. Cameron JS. Proteinuria and progression in human glomerular disease. *Am J Nephrol* 1990; 13(suppl 1):81-7
21. Eddy AA. Interstitial nephritis induced by protein overload proteinuria. *Am J Pathol* 1989; 135:719-33
22. Lianos EA, Bresnahan BA, Pan C. Mesangial cell immune injury synthesis, origin and role of eicosanoids. *J Clin Invest* 1991; 88:623-31
23. Rosenblum ND. The mesangial matrix in the normal and sclerotic glomerulus. *Kidney Int* 1994; 45 (suppl 45):58-63
24. Rennke HG. How does glomerular epithelial cell injury contribute to progressive glomerular damage ? *Kidney Int* 1994; 45 (suppl 45):58-63

25. Kriz W, Elger M, Nagata M et al. The role of podocytes in the development of glomerular sclerosis. *Kidney Int* 1994; 45 (suppl 45):64-72
26. Yamamoto T, Noble NA, Milder DE, Border WA. Sustained expression of TGF- $\beta$ , underlies development of progressive kidney fibrosis. *Kidney Int* 1994; 45:916-27
27. Floege J, Barns MW, Alpers CE et al. Glomerular cell proliferation and PDGF expression precedes glomerulosclerosis in the remnant kidney model. *Kidney Int* 1992; 41:297-309
28. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease : The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation and intrinsic renal disease. *N Engl J Med* 1982; 307:652-9
29. Brenner BM. Hyperfiltration in remnant nephron : A potential response to renal ablation. *Am J Physiol* 1989; 241:F85—F93

30. Futrakul P, Poshyachinda M, Mitrakul C et al. Focal sclerosing glomerulonephritis : A kinetic evaluation of hemostasis and the effect of anticoagulant therapy : A controlled study. *Clin Nephrol* 1978; 10:180-6
31. Futrakul P, Poshyachinda M, Mitrakul C. Hypercoagulability in the nephrotic syndrome : Use of anticoagulation, in Zurukzoglu W, Papadimitrio M, Pырpasopoulos M, Sion M, Zamboulis C (eds). *Advances in Basic Nephrology, 8<sup>th</sup> Int Congr Nephrol, Athens, 1981. Basel, Karger pp 197-201*
32. Futrakul N, Futrakul P, Poshyachinda M. Transient procoagulant state of glomerular endothelium in mesangial proliferative nephrosis (MesP-NS). *The FASEB Journal* 1993; 7:A220
33. Futrakul P. A new therapeutic approach of nephrotic syndrome associated with focal segmental glomerulosclerosis. *Internat J Ped Nephrol* 1980; 1:18-21
34. Stiehm ER, Kuplic LS, Nehling DT. Urinary fibrin split products in human renal disease. *J Lab Clin Med* 1971; 77:843

35. Futrakul P. Coagulation in glomerulonephritis and nephritic syndrome : Its therapeutic intervention. In : Takeuchi T et al (eds). *Asian Manual of Nephrology*. SEAMIC, Tokyo 1981 pp 89-95
36. Cameron JS. Coagulation and thromboembolic complications in the nephrotic syndrome. *Kidney Int* 1985; 28:429-39
37. Llach F, Papper S, Massry SG. The clinical spectrum of renal vein thrombosis : Acute and chronic. *Am J Med* 1979; 69:819-27
38. Futrakul P, Boonjunwetwat D, Pochanugool C, Sitprijia V, Futrakul N, Trakarnvanich T. Renal vein thrombosis in a severe form of renal disease. *Am J Nephrol* 1995; 15:364-6
39. Futrakul P, Sitprijia V, Yenrudi S. et al. Glomerular endothelial dysfunction determines disease progression : A hypothesis. *Am J Nephrol* 1997; 17:533-40
40. Futrakul N, Yenrudi S, Sensirivatana R, et al. Peritubular capillary flow determines tubulointerstitial disease in idiopathic nephrotic syndrome. *Ren Fail* 2000; 22:329-35

41. Bohle A, Mackensen-Haen S, Wehrmann M. Significance of postglomerular capillaries in the pathogenesis of chronic renal failure. *Kidney and Blood Press Res* 1996; 19:191-5
42. Lum H, Roebuck KA. Oxidative stress and endothelial cell dysfunction. *Am J Physiol Cell Physiol* 2001; 280:C719-741
43. Diamond JR, Bonventre JV, Karnovsky MJ. A role for oxygen free radicals in aminonucleoside nephrosis. *Kidney Int* 1986; 29:478-483
44. Wardle EN. Oxidative processes in glomerulonephritides : Additional facts. *Nephron* 2000; 85:103-6
45. Shah SV. Role of reactive oxygen metabolites in experimental glomerular disease. *Kidney Int* 1989; 35:1093-1106
46. Baliga R, Veda N, Shah SV. Oxidant mechanisms in glomerular disease; in Gonich HC (ed). *Current Nephrology*. St.Louis, Mosby 1997, pp 135-151



47. Kahsem A, Endoh M, Nomoto Y, Sakai N, Nakazawa H.  
FCOR expression on polymorphonuclear leukocytes  
and superoxide generation in IgA nephropathy.  
Kidney Int 1994; 45:868-875
48. Tengchaisri T, Chawengkirttikul R, Rachaphaew N, Reutrakul V,  
Sangsuwan R, Sirisinha S. Antitumor activity of triptolide  
against cholangiocarcinoma growth in vitro and in  
hamsters. Cancer Letters 1998; 133:169-175
49. Marshall JP, Warso Am, Lands EMW. Selective  
microdetermination of lipid hydroperoxide. Anal Biochem  
1985 145:192-199
50. Beutler E, Derron O, Kelly MB. Improved method for  
determination of blood glutathione. J Lab Clin Med  
1963; 61:882-888
51. Cevat IT, Tuli A, Yuregir TG. Evaluation of reference values  
for erythrocyte glutathione. Clin Chem Acta  
1996; 256:189-196

52. Liu ZT, Chin N, Kiser DM, Bigler NW. Specific spectrophotometry of ascorbic acid in serum or plasma by use of ascorbate oxidase. *Clin Chem* 1982; 28:2225-2228
53. Motchnik PM, Frei B, Ames BN. Measurement of antioxidants in human blood plasma. *Methods Enzymol* 1994; 234:269-279
54. Futrakul P, Poshyachinda M, Futrakul N, et al. Intrarenal hemodynamic alteration and tubular function in nephrotic syndrome associated with focal segmental glomerulosclerosis (FSGS) : A pathogenetic and therapeutic implication. In: Andreucci VE, Dal Canton A (eds), *Current Therapy in Nephrology*. Wichtig Editore, Milano 1993, pp. 1107-114
55. McIntyre M, Bohr DF, Dominiczak AF. Endothelial function in hypertension. *Hypertens* 1999; 34:539-545
56. Koja G, Hanison D. Interactions between NO and reactive oxygen species; pathophysiologic importance in atherosclerosis, hypertension, diabetes and heart failure. *Cardiovasc Res* 1999; 43:562-571

57. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. *Circ Res* 1999; 85:753-766
58. Hasoelwander D, Young IS. Oxidative stress in chronic renal failure. *Free Rad Res* 1998; 29:1-11
59. Galli F, Canestrari F, Bellomo G. Pathophysiology of the oxidative stress and its implication in uremia and dialysis. *Contrib Nephrol* 1999; 127:1-31
60. Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients : a hypothesis on the role of oxidative stress and other non-traditional cardiac risk factors. *J Am Soc Nephrol* 1997; 8:475-486
61. Kitiyakara C, Gonin J, Massy Z, Wilcox CS. Non-traditional cardiovascular disease risk factors in end-stage renal disease : oxidative stress and hyperhomocysteinemia. *Curr Opin Nephrol Hypertens* 2000; 9:477-487

62. Baud L, Fourqueray B, Phillippe C. Reactive oxygen species as glomerular autocoids. *J Am Soc Nephrol* 1992; 2(suppl):132-138
63. Kitamura M, Fine LG. The concept of glomerular self-defense. *Kidney Int* 1999; 55:1639-1671
64. Lo SK, Janakideve K, Lai L. Hydrogen peroxide induced increase in endothelial cell adhesiveness is dependent on ICAM-1 activation. *Am J Physiol* 1993; 264:L406-412
65. Baeuerle PA, Henkel T. Function and activation of NF-kB in the immune system. *Ann Rev Immunol* 1994; 12:141-179
66. Futrakul N, Panichakul T, Chaisuriya P, Sirisinha S, Patumraj S, Futrakul P. Endothelial cell cytotoxicity and renal hypoperfusion in idiopathic nephrotic Syndrome. *Nephron* 2000; 86:241-242

67. Futrakul N, Panichakul T, Chaisuriya P, Sirisinha S, Futrakul P, Patumraj S. Endothelial cell cytotoxicity induced by nephrotic serum. In: Sirisinha S, Chaiyaroj SC, Tapchaisri F (eds). 2<sup>nd</sup> Congress of the Federation of Immunological Societies of Asia-Oceania, Bangkok. Monduzzi Editore 2000, pp. 27-31
68. Guijarro C, Egido J. Transcription factor-kappa B and renal disease. *Kidney Int* 2001; 59:415-424
69. Wei Z, Costa K, Al-Medhi AB, Dodia C, Muzykantor V, Fisher AB. Simulated ischemia in flow-adapted endothelial cells leads to generation of reactive oxygen species and cell signaling. *Circ Res* 1999; 85:682-689
70. Okada H, Woodcock-Mitchell J, Mitchell J, et al. Induction of plasminogen activator inhibitor type 1 and type 1 collagen expression on rat cardiac microvascular endothelial cells by interleukin-1 and its dependence on oxygen centered free radicals. *Circulation* 1998; 97:2175-2182

71. Schachter AD, Strom TB. Post-transplant recurrent FSGS :  
molecular in sight and future directions. *Nephron* 1999;  
82:300-305
72. Ou ZL, Natai Y, Notori Y. Transient and sequential expression  
of chemokine in RNA in blomeruli in puromycin  
aminonucleoside nephrosis. *Nephron* 2000; 85:254-257
73. Futrakul N, Yenrudi S, Futrakul P, et al. Peritubular capillary  
flow and tubular function in idiopathic nephritic  
syndrome. *Nephron* 2000; 85:181-182
74. Harris DCH. Tubulointerstitial renal disease.  
*Curr Opin Nephrol Hypertens* 2001; 10:303-313
75. de Cavanagh EMV, Leon Ferder MS, Larrasquedo F, et al :  
Higher levels of antioxidant defenses in enalapril-treated  
versus non-enalapril-treated hemodialysis patients.  
*Am J Kidney Dis* 1999; 34:445-455
76. Packer L. Vitamin C and redox cycling antioxidants. In:  
Packer L, Fuchs I (eds). *Vitamin C in health and disease*.  
New York, Marcel Dekker Inc 1997, pp. 95-121

77. Bowry VW, Mohr D, Cleary J, Stocker R. Prevention of tocopherol-mediated peroxidation in ubiquinol-10-free human low density lipo protein. *J Biol Chem* 1995; 270:5756-5763
78. Carr AC, Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and healthy effects in humans. *Am J Clin Nutr* 1999; 69:1086-1107
79. Edge R, Truscott TG. Prooxidant and antioxidant reaction mechanisms of carotene and radical interactions with vitamins E and C. *Nutrition* 1997; 13:992-994
80. Tsao CS. An overview of ascorbic acid and chemistry and biochemistry. In: Packer L, Fuchs J (eds). *Vitamin C in health and disease*. New York, Marcel Dekker Inc 1997; pp. 25-58
81. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. *Circulation* 1998; 97:2222-2229

82. Nath KA, Salaherdeen AR. Induction of renal growth and injury in the intact rat kidney by dietary deficiency of antioxidants. *J Clin Invest* 1990; 86:1179-1192
83. Hagiwara K, Naito K, Kurokawa Y, et al. Kidney injury induced by lipid peroxide produced by vitamin E deficiency and GSH depletion in rats. *J Nutr Sci Vita Minol* 1991; 37:99-107
84. Sadava D, Luo PW, Casper J. Induction of renal damage in rats by a diet deficient in antioxidants. *Nutr Res* 1996; 16:1607-1612
85. Lee HS, Jeong JY, Kim BC, et al. Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. *Kidney Int* 1997; 51:1151-1159
86. Trachtman H, Schwob N, Maesaka J, et al. Dietary vitamin E supplementation ameliorates renal injury in chronic paromycin aminonucleoside nephropathy. *J Am Soc Nephrol* 1995; 5:1811-1819
87. Fryer MT. Vitamin E as a protective antioxidant in progressive renal failure. *Nephrology* 2000; 5:1-7



88. Glassock RJ. Therapy of idiopathic nephritic syndrome in adults. *Am J Nephrol* 1993; 13:422-428
89. Wehrmann M, Bohle A, Held H, Schumm G, Kendziom H, Pressler H. Long-term prognosis of patients with focal segmental glomerulosclerosis. *Clin Nephrol* 1978; 10:213-218
90. Futrakul P, Futrakul N, Sitprijia V. Enhanced renal perfusion improves function in severe nephrosis with focal segmental glomerulosclerosis. *Nephrology* 1995; 1:51-57
91. Futrakul N, Tosukhowong P, Valyapongpichit Y, Tipprukmas N, Futrakul P, Patumraj S. Oxidative stress and hemodynamic maladjustment in chronic renal disease : A therapeutic implication. *Ren Fail* 2002 in press.
92. นริสา พุตระกุล, ปิยะรัตน์ โตสุขวงศ์, ยุวดี วลัยพงษ์พิจิตร และคณะ  
ความผิดปกติจากสารอนุมูลอิสระกับภาวะหลอดเลือดไตหดรััดตัว  
กับการทำลายไต. วารสารราชบัณฑิต (กำลังตีพิมพ์ 2002)

## BIOGRAPHY

NAME Miss Narisa Futrakul

DATE OF BIRTH 19 March 1966

PLACE OF BIRTH Kansas, USA.

INSTITUTIONS ATTENDED - Mahidol University, 1986-1992  
Medical Degree  
- King Chulalongkorn Memorial  
Hospital 1995-1998  
- Diplomate, Thai Board of Internal  
Medicine

ADDRESS 102/16 Soi Ronachai 2, Sethsiri Road,  
Samsaennai, Phyathai, Bangkok 10400

ศูนย์วิทยุทางการแพทย์  
จุฬาลงกรณ์มหาวิทยาลัย

## PUBLICATION

This thesis has been accepted for publication in 5 international journals.

1. Futrakul N, Panichakul T, Chaisuriya P, Sirisinha S, Patumraj S, Futrakul P. Endothelial cell cytotoxicity and renal hypoperfusion in idiopathic nephrotic syndrome. *Nephron* 2000; 86:241-242
2. Futrakul N, Panichakul T, Chaisuriya P, Sirisinha S, Futrakul P, Patumraj S. Endothelial cell cytotoxicity induced by nephrotic serum. *Proceeding 2<sup>nd</sup> Congress of The Federation of Immunological Societies of Asia-Oceania, Bangkok, Monduzzi Editore, 2000 pp 27-31*
3. Futrakul N, Tosukhowong P, Valyapongpichit Y, Tipprukmas N, Futrakul P, Patumraj S. Oxidative stress and hemodynamic maladjustment in chronic renal disease : A therapeutic implication. *Ren Fail* 2002 (in press)
4. Futrakul N, Yenrudi S, Sensirivatana R, et al. Peritubular capillary flow determines tubulointerstitial disease in idiopathic nephrotic syndrome. *Ren Fail* 2000; 22:329-335
5. Futrakul N, Yenrudi S, Futrakul P, et al. Peritubular capillary flow and tubular function in idiopathic nephrotic syndrome. *Nephron* 2000; 85:181-182

---

---

# RENAL FAILURE

---

---

VOLUME 22  
NUMBER 2  
2000



ศูนย์วิทยทรัพยากร  
จุฬาลงกรณ์มหาวิทยาลัย

Dekker©•Pubs  
*Online Journals*  
[www.dekker.com](http://www.dekker.com)

CLINICAL STUDY

**PERITUBULAR CAPILLARY FLOW  
DETERMINES TUBULOINTERSTITIAL DISEASE  
IN IDIOPATHIC NEPHROTIC SYNDROME**

**Narisa Futrakul, Saowanee Yenrudi, Rajanee Sensirivatana,  
Dhevy Watana, Aimon Laohapaibul, Krisda Watanapenphaibul,  
Pornchai Kingwatanakul, Prasit Futrakul, and Sithivudh Futrakul**

Faculty of Medicine, The King Chulalongkorn Memorial Hospital,  
Bangkok, Thailand

**ABSTRACT**

The spatial relationship between renal perfusion and nephronal structure was determined in 51 nephrotic patients consisting of 11 patients with steroid sensitive, minimal change (MC) nephrosis, 12 patients with steroid resistant, mesangial proliferative (MesP) nephrosis and without tubulointerstitial fibrosis (TIF), 11 patients with steroid resistant, MesP nephrosis and with low grade TIF and 17 patients with focal segmental glomerulosclerosis (FSGS). The intrarenal hemodynamic study revealed a unique correlation between renal perfusion and nephronal structure. A normal or slight reduction in peritubular capillary flow observed in MC or mild MesP nephrosis correlates with an intact tubulointerstitial structure. A moderate reduction in peritubular capillary flow observed in steroid resistant, MesP nephrosis induces a low incidence of TIF. A severe reduction in peritubular capillary flow denotes a higher incidence of TIF as that observed in nephrosis with FSGS. Thus, it is of notion that the reduction in renal perfusion precedes the development of tubulo-

---

*Address correspondence to:* Narisa Futrakul, MD, Faculty of Medicine, The King Chulalongkorn Memorial Hospital, Rama IV Road, Bangkok 10330, Thailand. Tel (662) 256-4951, Fax (662) 256-4911; E-mail : yongmd2.chula.ac.th.

$$\text{Body surface area} = \frac{\text{body weight (kg)} \times 4 + 7}{90 + \text{body weight (kg)}}$$

### Vascular Function (Hemodynamic Assessment)

Simultaneous assessments of effective renal plasma flow (RPF) using  $^{131}\text{I}$ -labeled orthoiodohippuric acid (hippuran) and of glomerular filtration rate (GFR) using  $^{99\text{m}}\text{Tc}$ -labeled DTPA were determined by injecting the labeled materials intravenously into the left antecubital vein at zero time. A peritubular capillary flow (PTCF) is derived from the subtraction of glomerular filtration rate from renal plasma flow.

### Renal Histopathologic Study

The morphometric analysis was performed on the renal biopsied specimens by the method described elsewhere<sup>4</sup>. In brief, the kidney tissue was fixed in 4% buffered formalin and embedded in paraffin. Sections (2 $\mu\text{m}$ ) were prepared and stained with haematoxylin-eosin, periodic acid Schiff reagent (PAS), silver methenamine and Massons Trichrome. At least eight serial sections were prepared from each case and examined. The number of glomeruli varied from 10 to 35. The tubulointerstitial fibrosis (TIF) was quantitated in a single blind fashion by a pathologist who had no information regarding the hemodynamic value of each individual. The widening of interstitium was assessed by a point-count technique using a counting grid. This manner would cover most area in the renal cortex which was ascertained by determining at  $\times 100$  magnification and the result obtained was expressed as percent.

### STATISTICAL ANALYSIS

Comparison of the sample mean of two quantitative variables was determined by the non-parametric method using the Mann-Whitney test. The difference between groups was performed by Student's unpaired t-test. The linear regression analysis was used to correlate two quantitative variables. The scatter plot was the first step to correlate between two continuous variables. The Pearson correlation coefficient (  $r$  ) was used to quantify the strength of the linear relationship. The method of least square was calculated to estimate the regression equation (  $y = a \pm bx$  ) if the scatter plot seemed to be linear. Some relationship of the scatter plot data which had shown to be curvilinear, was further analysed to meet the criteria of straight line. P values below 0.05 were considered to be significant.

**Table 1.** Table 1 depicts the correlation between renal perfusion and tubulointerstitial structure. GFR = glomerular filtration rate, RPF = renal plasma flow, PTCF = peritubular capillary flow, TIF = tubulointerstitial fibrosis, MC-NS = minimal change nephrosis, MesP-NS = mesangial proliferative nephrosis, NS-FSGS = nephrosis associated with focal segmental glomerulosclerosis

Patients	RPF mL/min/ 1.73m <sup>2</sup>	PTCF mL/min/ 1.73m <sup>2</sup>	TIF %	GFR mL/min/ 1.73m <sup>2</sup>
Normal	600	480	0	120
Group 1:MC-NS (steroid-sensitiveness)	711 ± 92	584 ± 85	0	127 ± 26
Group 2:MesP-NS with no TIF (steroid-resistance)	491 ± 52	392 ± 50	0	99 ± 14
Group 3:MesP-NS with TIF (steroid-resistance)	311 ± 67	235 ± 49	5 ± 2	78 ± 36
Group 4:NS-FSGS (severe)	179 ± 80	142 ± 69	58 ± 14	36 ± 18

documented in the steroid-resistant, mesangial proliferative nephrosis (group 2) and such a mild reduction in renal perfusion is generally unable to induce tubulointerstitial fibrosis. With a greater reduction in peritubular capillary flow (mean  $235 \pm 49$  mL/min/1.73 m<sup>2</sup>) in this severe category, such degree of perfusion deficit is then capable of inducing tubulointerstitial fibrosis. The above evidence simply implies that a substantial reduction in renal perfusion is prerequisite and precedes the development of nephronal death or tubulointerstitial fibrosis. Such a conceptual view of renal perfusion deficit inducing tubulointerstitial fibrosis is well illustrated by the multiple regression analysis approach in which the peritubular capillary flow is inversely proportional to the incidence of tubulointerstitial fibrosis (Figure 1). The development of tubulointerstitial fibrosis would occur as the reduction in peritubular capillary flow approaching the fifty per cent area of normal value. As the reduction in peritubular capillary flow becomes progressive, there is also a steady increase in the incidence of tubulointerstitial fibrosis. Such reduction in renal perfusion has been uniquely observed in a variety of chronic glomerulonephritides<sup>5</sup>.

The result of this intrarenal hemodynamic study appears to be somewhat contradictory to the general belief that the nephronal death such as tubulointerstitial fibrosis is the cause rather than the effect of the renal perfusion deficit. A similar observation to us was also remarked by Bohle and associates<sup>6</sup> who had denoted that the degree of tubulointerstitial fibrosis correlated inversely with the intensity of postglomerular capillary patency. In addition, Truong and Farhood<sup>7</sup> demonstrated in their experimental model

- dysfunction determines disease progression : A hypothesis. *Am J Nephrol* 17:533-540, 1997.
2. Thomas SE, Anderson S, Gordon KL, Oyama TT, Shankland SJ, Johnson RJ: Tubulointerstitial disease in aging : Evidence for underlying peritubular apillary damage, a potential role for renal ischemia. *J Am Soc Nephrol* 9:231-242, 1998.
  3. Futrakul P, Poshyachinda M, Futrakul N, Chaiwatanarat T, Sensirivatana R, Thamaree S, Watana D, Kingwatanakul D: Intrarenal hemodynamics alterations and tubular functions in nephrotic syndrome associated with focal segmental glomerulosclerosis (FSGS): A pathogenetic and therapeutic implication; in Andreucci VE, Dal Canton A (eds): *Current Therapy in Nephrology*. Milan, Wichtig 1993, pp 107-114.
  4. Bohle A, Glomb D, Grund KE, Mackensen S: A correlation between relative interstitial volume of the renal cortex and serum creatinine concentration in minimal changes with nephrotic syndrome and in focal sclerosing glomerulonephritis. *Virch Arch A Patho Anat Histol* 376:221, 1977.
  5. Futrakul P, Poshyachinda M, yenrudi S, et al: Intrarenal hemodynamic abnormality in severe form of glomerulonephritis : Therapeutic benefit with vasodilators. *J Med Assoc Thai* 75:375-385, 1992.
  6. Bohle A, Mackensen-Haen S, Wehrmann M: Significance of postglomerular capillaries in the pathogenesis of chronic renal failure. *Kidney and Blood Press Res* 19:191-195, 1996.
  7. Truong LD, Farhood A, Tasby J, Gillum D: Experimental chronic renal ischemia : Morphologic and immunologic studies. *Kidney Int* 41:1676-1689, 1992.
  8. Futrakul P, Poshyachinda M, Mitrakul C: Focal sclerosing glomerulonephritis : A kinetic evaluation of hemostasis and the effect of anticoagulant therapy : A controlled study. *Clin Nephrol* 10:180-186, 1978.
  9. Futrakul P, Futrakul N, Sitprijia V: Enhanced renal perfusion improves function in severe nephrosis with focal segmental glomerulosclerosis. *Nephrology* 1:51-57, 1995.
  10. Ito S, Yasaki T: Effect of dipyridamole treatment in proteinuria in pediatric renal disease. *Nephron* 44:174-179, 1980.
  11. Futrakul N, Pochanugool C, Sitprijia V, Singkhwa V, Futrakul P, Yenrudi S, Sensirivatana R, Watana D, Poshyachinda M: Renal dysfunctions in glomerulonephropathy with rapidly declined renal failure. *Renal Failure* 18:557-565, 1996.
  12. De Jong PE, vander Meer J, vander Hem GK, de Zieuw D: Is the antiproteinuric effect of dipyridamole hemodynamically mediated? *Nephron* 50:292-294, 1988.
  13. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in rat. *J Clin Invest* 77:1993-2000, 1986.
  14. Stefanski A, Amann K, Ritz E: To prevent progression : Ace inhibitors, calcium antagonists or both ? *Nephrol Dial Transplant* 10:151-152, 1995.
  15. Marinides GN, Grogged GC, Cohen AH, Border WA : Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy. *Kidney Int* 37:749-757, 1990.



86 | 2 | 00

October 2000

# NEPHRON

S. Karger  
Medical and Scientific  
Publishers  
Basel · Freiburg  
Paris · London  
New York · New Delhi  
Bangkok · Singapore  
Tokyo · Sydney

**KARGER**

## Endothelial Cell Cytotoxicity and Renal Hypoperfusion in Idiopathic Nephrotic Syndrome

Narisa Futrakul<sup>a</sup> Tasanee Panichakul<sup>b</sup> Preedawan Chaisuriya<sup>b</sup> Stitaya Sirisinha<sup>b</sup>  
Suthiluck Patumraj<sup>a</sup> Prasit Futrakul<sup>a</sup>

<sup>a</sup>Department of Physiology, The King Chulalongkorn Memorial Hospital, and <sup>b</sup>Department of Immunology, Chulabhorn Research Institute, Bangkok, Thailand

Dear Sir,

The importance of the hemodynamically mediated renal disease progression has emerged inasmuch as the therapeutic intervention with immunosuppressive agents fails to counteract the accepted concept of immunologic mechanism as a determinant of disease progression and to prevent the severe form of glomerulonephropathy such as nephrosis associated with focal-segmental glomerulosclerosis from progressing to end stage renal failure [1]. In this regard, it has recently been demonstrated by intrarenal hemodynamics that a normal renal perfusion is usually associated with an intact nephron structure and function, whereas renal hypoperfusion is a unique characteristic observation documented in severe forms of idiopathic nephrosis associated with nephron death such as glomerulosclerosis and tubulointerstitial fibrosis [2]. In addition, it is of notion that there is a progressive reduction in renal perfusion, as the disease severity progresses [3]. This view is delineated by multiple regression analysis which demonstrates that the reduction in renal perfusion is inversely proportional to the intensity of tubulointerstitial disease [4]. Furthermore, Bohle et al. [5] also noted that there was an inverse correlation between the relative volume of the intertubular capillaries and the serum creatinine concentration.

The preceding information would raise an interesting issue as to whether there is any factor in the serum of the nephrotic patient

associated with clinical severity capable of inducing such a phenomenon of progressive reduction in renal perfusion. In order to address this specific issue, we performed an endothelial cell cytotoxicity test using sera from nephrotic patients as previously described [6]. In brief, the human endothelial cell line ECV 304 (American Tissue Culture Collection) in medium 199 with 10% fetal bovine serum, approximately  $2 \times 10^4$  cells/well of 96-well tissue culture plates, was incubated overnight at 37°C in a 5% CO<sub>2</sub> atmosphere. Sera from nephrotic patients were added in duplicate wells. The culture medium and 10% Triton X were used as controls that showed no cell lysis and 100% cell lysis, respectively. The testing cultures were incubated as above for an additional 48 h. After incubation, each well was washed with phosphate-buffered saline and then stained with crystal violet. The stained cells were lysed with acid alcohol solution, and the optical density (OD) was determined by using a microtiter plate reader (model 3550; Biorad) at 550 nm. The percentage of cytotoxicity was calculated by:

Percent cytotoxicity =

$$\frac{[1 - (OD_{\text{testing}} - OD_{\text{Triton x}})]}{OD_{\text{control}} - OD_{\text{Triton x}}} \times 100$$

The results of the endothelial cell cytotoxicity test using sera from nephrotic patients revealed (1) that endothelial cell cyto-

toxicity could be enhanced by sera from patients with both mild nephrosis associated with mesangial proliferation (mean  $18 \pm 9\%$  versus control  $1.8 \pm 0.8\%$ ) and severe nephrosis associated with focal-segmental glomerulosclerosis (mean  $40 \pm 9\%$ ) – the differences were statistically significant ( $p < 0.001$ ) and (2) that sera from patients with nephrosis associated with focal-segmental glomerulosclerosis induced a higher degree of endothelial cell cytotoxicity. Thus, the endothelial cell cytotoxicity test renders a supportive view that endothelial cell injury in vivo is likely to be spontaneously induced in the clinical setting of nephrosis.

In accordance with the higher incidence of endothelial cell cytotoxicity induced by sera from patients with nephrosis associated with focal-segmental glomerulosclerosis, it is likely to imply that a significant endothelial cell death would occur in the renal microcirculation in such severe disease and that this spontaneous endothelial cell cytotoxicity would explain the phenomenon of progressive reduction in renal perfusion uniquely observed in the severe form of nephrosis. The nature of such a factor that spontaneously induced endothelial cell cytotoxicity remains to be further elucidated. However, an immunocirculatory imbalance with predominant Th-1 cell activity has recently been proposed [7].

KARGER

Fax +41 61 306 12 34  
E-Mail karger@karger.ch  
www.karger.com

© 2000 S. Karger AG, Basel  
0028-2766/00/0862-0241\$17.50/0

Accessible online at:  
www.karger.com/journals/neph

Narisa Futrakul, MD  
Faculty of Medicine  
The King Chulalongkorn Memorial Hospital, Rama IV Road  
T-10330 Bangkok (Thailand)

## References

- 1 Glassock RJ: Therapy of idiopathic nephrotic syndrome in adults. *Am J Nephrol* 1993;13:422-428.
- 2 Futrakul P, Sitprija V, Yenrudi S, Poshyachinda M, Sensirivatana R, Watana D, Singklwa V, Jungthirapanich J, Futrakul N: Glomerular endothelial dysfunction determines disease progression: A hypothesis. *Am J Nephrol* 1997;17:533-540.
- 3 Futrakul P, Yenrudi S, Sensirivatana R, Kingwatanakul P, Futrakul N, Futrakul S: Renal perfusion and nephron structure. *Nephron* 1999;82:79-80.
- 4 Futrakul N, Yenrudi S, Futrakul P, et al: Peritubular capillary blood flow and tubulointerstitial disease in idiopathic nephrotic syndrome (unpubl. data).
- 5 Bohle A, Mackensen-Haen S, Wehrmann M: Significance of post glomerular capillaries in the pathogenesis of chronic renal failure. *Kidney Blood Press Res* 1996;19:191-195.
- 6 Tengchaisri T, et al: Antitumor activity of tritotide against cholangiocarcinoma growth in vitro in hamsters. *Cancer Let* 1998;133:169-175.
- 7 Daniel V, Trautmann Y, Konrad M, Nayir N, Schärer K: T-lymphocyte populations, cytokines and other growth factors in serum and urine of children with idiopathic nephrotic syndrome. *Clin Nephrol* 1997;47:289-297.

## Book Review

---

G.G. Fogazzi, C. Ponticelli, E. Ritz

### **The Urinary Sediment: An Integrated View, ed 2**

Oxford University Press, Oxford, 1999  
ISBN 0-19-263074-1

This is a beautifully illustrated 186-page book on the urinary sediment. It has the most excellent phase contrast illustrations of urinary sediment I have ever seen in print, with some interference, fluorescent, plain and polarized microscopy photographs. It is a most practical work with detailed instructions on the preparation of the sediment, and even how one sets up a phase contrast microscope. The integration of a pleasant and amusing chapter on the history of urine microscopy by Cameron, and a chapter on the findings of the sediment in various diseases is well illustrated by superb glomerular histology. It is debatable whether the history and renal histology should be included in the book which is otherwise a most excellent manual and atlas of the urinary sediment. This is of course purely a matter of personal preference for the integrated approach, depending on the reader. However, this is still an extraordinary book, and the best buy on the market. It should be owned by every nephrologist, and those internists who still examine urine sediments. It is essential for nephrologists in training. The beauty of its presentation will give pleasure to all who read it, and the Oxford University Press is to be congratulated on the finished product, and the authors for their writing this fine book.

*G.M. Berlyne*

REPRINTED FROM:

*2<sup>nd</sup> Congress of the*

***Federation of  
Immunological  
Societies of  
Asia-Oceania***



Bangkok (Thailand), January 23-27, 2000

Editors

STITAYA SIRISINHA  
SANSANEE C. CHAIYAROJ  
PRAMUAN TAPCHAI SRI



ศูนย์วิทยุโทรพยากร  
จุฬาลงกรณ์มหาวิทยาลัย

MONDUZZI EDITORE

***INTERNATIONAL PROCEEDINGS-DIVISION***

# Endothelial Cell Cytotoxicity Induced by Nephrotic Serum

N. Futrakul, T. Panichakul, P. Chaisuriya, S. Sirisinha,  
P. Futrakul and S. Patumraj

*King Chulalongkorn Memorial Hospital and  
Chulabhorn Research Institute, Bangkok, Thailand*

## Summary

An endothelial cell cytotoxicity (ECC) could be enhanced in accord with the clinical severity in vitro by sera of both mild and severe forms of nephrosis. Such finding correlated with the intrarenal hemodynamics which demonstrated a mild reduction in renal plasma flow in mesangial proliferative nephrosis and a severe renal perfusion deficit in nephrosis with focal segmental glomerulosclerosis. Thus, the magnitude of ECC observed in vitro study is likely to reflect the in vivo reduction in renal perfusion in these nephrotic patients.

## Introduction

A glomerular endothelial cell dysfunction has been delineated in glomerular inflammation such as idiopathic nephrotic syndrome [1]. By virtue of its vicinity with the inflammatory site in the glomerulus, the glomerular endothelium is likely to be perturbed by the process of inflammation. In this regard, a glomerular endothelial dysfunction has been supported in active nephrosis by 2 lines of evidence. First, the glomerular endothelial phenotype expression of normal anticoagulant activity is altered in nephrosis and becomes procoagulant. Such a procoagulant activity is associated with blood hypercoagulability, blood hyperviscosity and local intravascular coagulation which is reflected by altered kinetic studies of platelet and fibrinogen and elevated level of fibrin degradation product in the

serum and urine of nephrotic patient [2-5]. Second, the glomerular endothelial phenotype expression of normal vasodilation is altered and becomes provasoconstrictive. Such a provasoconstrictive activity is substantiated by the intrarenal hemodynamic study of nephrotic patients in which a characteristic reduction in renal perfusion is generally observed [6,7].

The significance of glomerular endothelial dysfunction and its hemodynamic impact has recently been related to the pathogenesis of renal disease progression. It is of notion that (1) a mild reduction in renal perfusion as that observed in mesangial proliferative nephrosis is usually associated with an intact structure and function of the kidney (2) the reduction in renal perfusion in the severe category of nephrosis usually *precedes* the development of tubulointerstitial fibrosis or glomerulosclerosis and (3) the magnitude of damage to the nephronal structure increases as the renal perfusion becomes progressively decreased [8].

The slight reduction in renal perfusion observed in mesangial proliferative nephrosis and the progressive reduction in renal perfusion documented in nephrosis associated with focal segmental glomerulosclerosis are indeed interesting phenomena. The difference in the amplitude of renal perfusion deficit between the two subsets of nephrosis (mild and severe) would likely reflect the difference in the underlying severity of glomerular endothelial injury. In addition, the spontaneous pattern of glomerular endothelial injury observed in the clinical setting of human nephrosis renders a strong suspicion that plasma or serum would be the good candidate for such source of endothelial injury. It is therefore, interesting to know whether an injury to the endothelial cell can plausibly be induced *in vitro* by the patient's serum.

## Material and Method

### 1. Endothelial Cell Cytotoxicity Test

Human endothelial cell line (ECV 304, ATCC : American tissue culture collection) in M199 with 10% FBS approximately  $2 \times 10^4$  cells per well of 96-well tissue culture plate were incubated overnight at 37°C with 5% CO<sub>2</sub> atmosphere by the previously described method [9]. Sera from nephrotic patients (11 patients with mesangial proliferation and 8 patients with focal segmental glomerulosclerosis) were added in duplicate wells. The culture medium and 10% tritonX were used as controls that showed no cell lysis and 100% cell lysis, respectively. The testing cultures were incubated as above for an additional 48 h. After the incubation, each well was washed with PBS and then stained with crystal violet. The stained cells were lysed with acid alcohol solution and the optical density was determined by a microtiter plate reader (Model 3550, Biorad) at 550 nm.

The percentage of cytotoxicity was calculated by the equation as follow:

$$\text{Percent cytotoxicity} = \left[ 1 - \frac{(\text{OD}_{\text{testing}} - \text{OD}_{\text{triton X}})}{(\text{OD}_{\text{control}} - \text{OD}_{\text{triton X}})} \right] \times 100$$

## 2. Glomerular Endothelial Function Determined by Intrarenal Hemodynamic Study

The hemodynamic aspect of glomerular endothelial function was assessed in nephrotic patient by the method of simultaneous determinations of renal plasma flow using  $^{131}\text{I}$  – labeled orthiodohippuric acid (hippuran) and of glomerular filtration rate using  $^{99\text{m}}\text{Tc}$  – labeled diethylenetriamine pentaacetic acid (DTPA) as previously described [6].

### Result

As depicted in Table 1, the endothelial cell cytotoxicity induced by sera from mesangial proliferative nephrosis was  $18 \pm 9$  % as compared to  $40 \pm 9$  % induced by sera from nephrosis associated with focal segmental glomerulosclerosis, the difference between the two groups was statistically significant;  $p < .001$ .

The intrarenal hemodynamic study revealed a mild reduction in renal plasma flow (mean  $491 \pm 71$  ml/min/ $1.73 \text{ m}^2$ ) in mesangial proliferative nephrosis and a moderately severe reduction in renal plasma flow (mean  $285 \pm 89$  ml/min/ $1.73 \text{ m}^2$ ) in nephrosis with focal segmental glomerulosclerosis.

Table 1 illustrated the endothelial cell cytotoxicity and renal plasma flow in idiopathic nephrotic syndrome

EC = endothelial cell, MesP-NS = mesangial proliferative nephrosis, NS-FSGS = nephrosis with focal segmental glomerulosclerosis

	EC Cytotoxicity %	Renal Plasma Flow ml/min/ $1.73 \text{ m}^2$
Normal Control (n = 5)	$1.8 \pm 0.8$	$598 \pm 80$
	$p < .001$	
MesP-NS (n = 11)	$18 \pm 9$	$491 \pm 71$
	$p < .001$	
NS-FSGS (n = 8)	$40 \pm 9$	$285 \pm 89$

## Discussion

The result of this *in vitro* study indicates that serum from the nephrotic patient can induce endothelial cell cytotoxicity. The serum derived from mild case of nephrosis associated with mesangial proliferation significantly enhances a greater index of endothelial cell cytotoxicity than the control ( $18 \pm 9$  % versus  $1.8 \pm 0.8$  %). The induction of endothelial cell cytotoxicity is even greater by the serum derived from the severe form of nephrosis associated with focal segmental glomerulosclerosis than that of the mesangial proliferative nephrosis ( $40 \pm 9$  % versus  $18 \pm 9$  %). This *in vitro* study does in fact support of what one would expect the glomerular endothelial cell injury to naturally occur in the clinical setting of nephrosis *in vivo*.

The magnitude of endothelial cell cytotoxicity observed in these two subsets of nephrosis also concurs with the glomerular endothelial cell function determined by an intrarenal hemodynamic study. In mild form of nephrosis associated with mesangial proliferation, the mild reduction in renal plasma flow ( $491 \pm 71$  ml/min/1.73 m<sup>2</sup>; control  $598 \pm 80$  ml/min/1.73 m<sup>2</sup>) observed agrees with the low incidence of endothelial cell cytotoxicity. Similarly, there is a greater degree of reduction in renal plasma flow ( $285 \pm 89$  ml/min/1.73 m<sup>2</sup>) documented in severe nephrosis associated with focal segmental glomerulosclerosis of which it is in accord with the higher endothelial cell cytotoxicity index.

The preceding information of endothelial cell cytotoxicity induced by the nephrotic serum would address to a specific issue relating to the mechanism of renal disease progression or damage to the nephronal structure. Inasmuch as the glomerular endothelial function associated with its hemodynamic impact or renal perfusion has been proven to be the determinant of nephronal structure and function, a further exploration as to what would be the likely trigger of endothelial cell cytotoxicity in severe form of nephrosis and if so, how to prevent it from such injury would be the appropriate issues that need to be addressed in future.

## References

1. Futrakul P, Sitprija V, Yenrudi S, Poshyachinda M, Sensirivatana R, Watana D, Singkhwa V, Jungthirapanich J, Futrakul N. Glomerular endothelial dysfunction determines disease progression : a hypothesis. *Am J Nephrol* 17:533-40, 1997
2. Futrakul P, Poshyachinda M, Mitrakul C. Hypercoagulability in the nephrotic Syndrome : Use of anticoagulation, in Zurukzoglu W, Papadimitrio M, Pырpasopoulos M, Sion M, Zamboulis C (eds). *Advances in Basic Nephrology*, 8<sup>th</sup> Int Congr Nephrol Athens, Basel, karger, pp 296-301, 1981



3. Futrakul P. Coagulation in glomerulonephritis and nephrotic syndrome : Its therapeutic intervention. In Takeuchi T, Sugino N, Ota K (eds). Asian Manual of Nephrology, SEAMIC, Tokyo, pp 89-95, 1981
4. Futrakul N, Futrakul P, Poshyachinda M. Transient procoagulant state of Glomerular endothelium in mesangial proliferative nephrosis (MesP-NS). FASEB Journal 7:A220, 1993
5. Futrakul P, Poshyachinda M, Mitrakul C. Focal sclerosing glomerulonephritis. A kinetic evaluation of hemostasis and the effect of anticoagulant therapy : A controlled study. Clin Nephrol 10:180-186, 1978
6. Futrakul P, Poshyachinda M, Futrakul N, Chaiwatanarat T, Sensirivatana R, Thamaree S. Intrarenal hemodynamic alterations and tubular functions in nephrotic syndrome. A pathogenetic and therapeutic implication. In Andreucci VE, Dal Canton A (eds). Current Therapy in Nephrology, Wichtig Editore, Milano pp 107-114, 1993
7. Futrakul N, Poshanugool C, Sitprija V, et al. Renal dysfunctions in glomerulonephropathy with rapidly declined renal failure. Renal Failure 8:557-565, 1996
8. Futrakul P, yenrudi S, Sensirivatana R, Kingwatanukul P, Futrakul N, Futrakul S. Renal perfusion and nephronal structure. Nephron 82:79-80, 1999
9. Tengchaisri T, Chawengkirttikul R, Rachaphaew N, Reutrakul V, Sangsuwan R, Sirisinha S. Antitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamsters. Cancer Letters 133:169-175, 1998

ศูนย์วิทยทรัพยากร  
จุฬาลงกรณ์มหาวิทยาลัย

## Peritubular Capillary Flow and Tubular Function in Idiopathic Nephrotic Syndrome


Narisa Futrakul Saowanee Yenrudi Prasit Futrakul Thumronkprawat Cherdkiadtikul  
Aimon Laohapaibul Sithivudh Futrakul Rachanee Sensirivatana

Faculty of Medicine, The King Chulalongkorn Memorial Hospital, Bangkok, Thailand

Dear Sir,

The correlation between renal perfusion and nephron structure has recently been proposed [1]. In essence, a normal or balanced renal perfusion, as observed in minimal change disease, is usually associated with an intact nephron structure, absence of glomerulosclerosis or tubulointerstitial fibrosis, and a benign clinical course. On the contrary, nephron damage such as glomerulosclerosis and tubulointerstitial fibrosis is usually encountered in patients having a renal perfusion deficit or renal microvascular disease [2-4]. Such a correlation between renal perfusion and nephron structure does indeed have a clinical impact on therapeutic as well as preventive aspects, and thus the hemodynamic approach is regarded as a clinically useful, noninvasive instrument to serve the therapeutic purpose.

A correlation between tubulointerstitial structure and tubular function by means of determining the fractional excretion of filtered solutes, namely sodium, calcium, magnesium, phosphate, and uric acid, has also recently been implicated [5]. The study indicates that a normal tubular transport, which is reflected by a low fractional excretion of filtered solutes, implies an intact tubular or tubulointerstitial structure and that an abnormal tubular transport, which is reflected by a high fractional excretion of filtered solutes, suggests tubulointerstitial fibrosis. In this regard, there is also a linear correlation between tubular function and nephron structure by multiple regression analysis. Thus, the tubular function would provide



**Fig. 1.** Correlation between peritubular capillary flow (PTCB) and fractional excretion of filtered magnesium (FEMg). MC-NS = Minimal change steroid-sensitive nephrosis; MesP-NS = mesangial proliferative nephrosis; MesP-NS with TIF = mesangial proliferative nephrosis with tubulointerstitial fibrosis; NS-FSGS = nephrosis with focal segmental glomerulosclerosis.

another noninvasive diagnostic approach for the clinical practice.

Tubular preceding information regarding both correlations, one between renal perfusion and nephron structure and the other

between tubulointerstitial disease and tubular function, would render a suggestive view that there should also be a correlation between renal perfusion and nephron function. In this regard, such a correlation be-

tween peritubular capillary flow and tubular function has been calculated in various clinical subsettings of glomerulonephropathies, the results indicating that there is an inverse linear correlation between peritubular capillary flow and tubular function as determined by fractional excretion of filtered magnesium (FEMg). FEMg is always normal in the presence of normal peritubular capillary flow. As the peritubular capillary flow declines and approaches 50% of normal, there is an early detection of tubular dysfunction expressed as increasing FEMg. With a greater reduction in peritubular capillary flow, there is a higher amplitude of FEMg, as shown in figure 1.

Inasmuch as both peritubular capillary flow and tubular function are noninvasive diagnostic parameters, the significance of such tools is of clinical relevance. The tubular function can be easily determined and the result obtained can assist in differentiating the presence or absence of tubulointerstitial involvement. This should be helpful in avoiding an unnecessary renal biopsy in those nephrotic patients having normal tubular function. Similarly, information regarding renal perfusion also assists in therapeutic and preventive planning for those patients having a renal perfusion deficit.

## References

- 1 Futrakul P, Yenrudi S, Sensirivatana R, Kingwatanakul P, Futrakul N, Futrakul S: Renal perfusion and nephronal structure. *Nephron* 1999;82:79-80.
- 2 Guasch A, Heshimoto H, Sibley RK, Deen WM, Myers BD: Glomerular dysfunction in nephrotic humans with minimal changes or focal glomerulosclerosis. *Am J Physiol* 1991; 260:F728-F737.
- 3 Bohle A, Mackensen-Haen S, Wehrmann M: Significance of postglomerular capillaries in the pathogenesis of chronic renal failure. *Kidney Blood Press Res* 1996;19:191-195.
- 4 Futrakul P, Sitprija V, Yenrudi S, et al: Glomerular endothelial dysfunction determines disease progression: A hypothesis. *Am J Nephrol* 1997;17:533-540.
- 5 Futrakul P, Yenrudi S, Futrakul N, et al: Tubular function and tubulointerstitial disease. *Am J Kidney Dis* 1999;33:886-891.



ศูนย์วิทยุทรัพยากร  
จุฬาลงกรณ์มหาวิทยาลัย

Dear Dr. Futrakul,

Starting in 2000, *Renal Failure* became available on the World Wide Web in a full-text version. The objective was to provide readers with as many options as possible by offering the print version, the electronic version, or both. Publishing the electronic edition of *Renal Failure* brings many advantages. Readers have almost immediate access to the journal upon its publication, are able to search its contents easily, and have access to related information via convenient hyperlinks.

## RENAL FAILURE

*Editor in Chief:* William F. Finn, M.D.  
Department of Medicine  
University of North Carolina  
CB# 7155, 325 MacNider Bldg.  
Chapel Hill, NC, USA 27599  
Tel: 919-966-2561  
Fax: 919-966-4251  
Email: [wffinn@sharpshin.med.unc.edu](mailto:wffinn@sharpshin.med.unc.edu)

August 22, 2001

Dear Dr. Futrakul:

The enclosed *Copyright Transfer Agreement* gives the publisher, Marcel Dekker, Inc., the publication rights necessary for effective and broad-based distribution and allows the publisher to protect the intellectual property of your work. To accomplish this, each article must have a signed copyright transfer agreement prior to submission for publication.

Your manuscript "**Oxidative stress and hemodynamic maladjustment in chronic renal disease: a therapeutic implication**" (MS01057) has been accepted for publication and will appear in *Renal Failure*, 2002. In order to complete the processing, **please sign the enclosed form along with any co-authors and return it with original signatures. Please return to me by September 15, 2001 or sooner.**

Your manuscript will be returned to you via Email, mail otherwise, for you to review after editing has been completed. You will be asked to review the manuscript and return it promptly for submission to the publisher.

Sincerely,  
William F. Finn, M.D.  
Editor-in-Chief, Renal Failure

WFF:psf

Oxidative Stress and Hemodynamic Maladjustment in Chronic Renal  
Disease : A Therapeutic Implication

Narisa Futrakul, Piyaratana Tosukhowong, Yuvadee Valyapongpichit,  
Numdee Tipprukmas, Prasit Futrakul, Suthiluk Patumraj

Department of Physiology, Biochemistry and Pediatrics,  
King Chulalongkorn Memorial Hospital,  
Rama IV Road, Bangkok 10330, Thailand.

Tel (662) 2564951, Fax (662) 2564911

E-mail address : [prasitfu@loxinfo.co.th](mailto:prasitfu@loxinfo.co.th)

ศูนย์วิทยทรัพยากร  
จุฬาลงกรณ์มหาวิทยาลัย

**ABSTRACT**

Hemodynamic maladjustment with predominant constriction at the efferent arteriole has been encountered in a variety of clinical settings of glomerulonephropathies. In essence, it induces not only intraglomerular hypertension but also exaggeratedly reduces the peritubular capillary flow which supplies the tubulointerstitial compartment. The hemodynamic maladjustment is believed to reflect a glomerular endothelial cell dysfunction. In this regard, oxidative stress and antioxidant defect are likely responsible for the glomerular endothelial dysfunction. Improvement in renal function was accomplished following the correction of oxidant and antioxidant imbalance with antioxidant therapy and vasodilators. Following such therapy, there was a correction in hemodynamic maladjustment with a decline in intraglomerular hydrostatic pressure and an increase in renal perfusion with a subsequent increase in renal functions namely creatinine clearance, glomerular filtration rate and a decline in FEMg.



Key Words : Hemodynamic, Chronic renal failure, Intraglomerular hypertension, Oxidant, Antioxidant, Vasodilators, Glomerular endothelial dysfunction.

## INTRODUCTION

The pathogenetic mechanism of renal disease progression with particularly relevant to the development of tubulointerstitial fibrosis in chronic renal disease is complex which implicates both hemodynamic and non-hemodynamic (immunologic) factors(1). Due to the unsuccessful attempt of immunosuppressant in preventing the progression of renal disease, the focus of interest has switched toward the issue of hemodynamic impact upon the mechanism of renal disease progression. Within this context, it has recently been demonstrated that there is a spatial relationship between renal perfusion and nephronal structure. A normal renal perfusion is usually associated with an intact nephronal structure with no tubulointerstitial disease such as that observed in steroid-sensitive, minimal change or mild mesangial proliferative nephrosis. In contrast, a reduction in renal perfusion such as peritubular capillary flow observed in nephrosis associated with focal segmental glomerulosclerosis generally encounters nephronal damage such as tubulointerstitial fibrosis(2). Furthermore, Bohle and associates(3) also denoted that the degree of tubulointerstitial fibrosis correlated inversely with the intensity of postglomerular capillary patency. The cause-and-effect relationship between renal perfusion and nephronal structure has been implicated by the observation in steroid-resistant mesangial proliferative nephrosis that the reduction in peritubular capillary flow precedes the development of tubulointerstitial fibrosis(4).

The reduction in renal perfusion is likely to be a reflection of glomerular endothelial dysfunction. The endothelial cell in nephrosis expresses procoagulant instead of anticoagulant surface and vasoconstrictive instead of vasodilating activity, thereby reducing the renal perfusion(2). In this regard, an experimental study mimicing glomerular endothelial cell injury has recently been demonstrated that serum of nephrotic patient is capable of inducing endothelial cell cytotoxicity in vitro. That the greater incidence of endothelial cell cytotoxicity is derived from the serum of severe nephrosis associated with focal segmental glomerulosclerosis whereas the serum from mesangial proliferative nephrosis induces a low incidence of endothelial cell cytotoxicity. Furthermore, it is also denoted that the degree of in vitro endothelial cell cytotoxicity correlates with the magnitude of reduction in renal plasma flow in vivo determined by the intrarenal hemodynamic study(5).

The preceding information has raised an interesting issue as to what would be the factor responsible for the induction of such endothelial cell cytotoxicity and dysfunction. Inasmuch as reactive oxygen species is capable of not only inducing proteinuria and nephronal damage in experimental model of puromycin aminonucleoside in animal(6), but also participating in a variety of clinical setting of glomerulonephritides(7-11), it is therefore of interest to perform in this study an assessment of oxidant and antioxidant status in nephrotic patients as well as in a group of patients associated with chronic renal failure who are likely to progress to an end-stage renal disease. If there would be any evidence of oxidative stress, it would also be interested to see whether a

correction of oxidant / antioxidant imbalance would improve the renal function and retard the progression of renal disease in these patients.

## MATERIAL AND METHODS

Fifteen patients associated with idiopathic nephrotic syndrome (8 patients with focal segmental glomerulosclerosis and 7 patients with mesangial proliferation) and 9 patients associated with chronic renal failure were included and subject to the following studies.

### I. Oxidant and Antioxidant Study

Ten milliliters of blood was drawn from the vein. Blood was placed into heparinized tube and centrifuged at 1500 g. for 15 minutes to separate plasma and RBCs. The RBCs were washed three times with cold saline, and the erythrocyte pellets were frozen at  $-20^{\circ}\text{C}$  until further analysis.

#### A. Lipid Peroxidation (MDA)

MDA was assessed by thiobarbituric acid (TBA) colorimetric assay of hydroperoxides. The TBA assay was performed using a modification of the technique described by Askawa and Matsushita (12).

#### B. Glutathione (GSH)

Determination of glutathione in the erythrocytes was made by colorimetric methods of Beutler E et al(13), using the glutathione disulfide reductase-DTNB [5-5'-dithiobis (2-nitrobenzoic acid)] to react with sulfhydryl compound and yield a stable yellow color. GSH concentration in the erythrocytes was expressed as  $\mu\text{ mol/g}$  hemoglobin(14). The hemoglobin concentration was assayed by using a cyanmethemoglobin technique.

#### C. Vitamin C

Ascorbic acid in serum and plasma was determined by specific enzymatic spectrophotometric method. Samples were analysed indirectly by measuring the absorbance at 593 nm(15).

#### D. Vitamin E

Vitamin E was assayed by the modified Emmeric and Engle's method(16). The oxidation of xylene-extracted tocopherols from the blood sample by ferric chloride and the pink complex of ferrous ions with bathophenanthroline was measured colorimetrically at 536 nm.

#### E. Glutathione peroxidase (GSH-Px)

GSH-Px activity was determined according to Gunzler et al(17), with modification by following oxidation of the reduced form of nicotinamide-adenine dinucleotide phosphate (NADPH) measured at 340 nm.



## II. Renal Function Studies

### A. Glomerular Function

A glomerular filtration rate was performed by measuring the 10-hour endogenous creatinine clearance (CCr) or glomerular filtration rate (GFR) by the radioisotope technique using  $^{99m}\text{Tc}$ -labeled diethylene triamine pentaacetic acid (DTPA) and the value was converted to the body surface area of  $1.73 \text{ m}^2$  by the method of calculation :

$$\text{Body surface area} = \frac{\text{body weight (kg)} \times 4 + 7}{90 + \text{body weight (kg)}}$$

Intraglomerular pressure (PG mm Hg) was assessed by the method of calculation as previously described(18).

### B. Tubular Function

Tubular transport was assessed by a 10-hour urinary collection during fasting. Blood drawn at the end of the test and urine were analysed for creatinine, magnesium and protein. A reflection of tubular transport was derived from the determination of fractional excretion (FE) of filtered solute namely magnesium (Mg). The FE Mg was calculated through the formula.

$$\text{FE Mg} = \frac{U_p \text{ Mg}}{U_p \text{ Creatinine}} \times 100\%$$

The normal value by FE Mg is  $\leq 2.2\%$

### C. Vascular Function

The renal plasma flow (RPF) value using  $^{131}\text{I}$ -labeled orthoiodohippuric acid (hippuran) and the renal afferent (RA) and efferent arteriolar resistance (RE) were determined by the previously described method(19). A peritubular capillary flow (PTCF) is derived from the subtraction of glomerular filtration rate from renal plasma flow.

## III. Mode of Therapy

All of these 24 patients were treated with enhanced renal perfusion therapy, which consisted of (a) angiotension converting enzyme inhibitor such as cilazapril 1.25-10 mg/day or enalapril (0.25-1 mg/kg/day) or AII receptor antagonist 50-100 mg/day (b) calcium channel blocker isradipine 2.5-10 mg/day and (c) antiplatelet agent dipyridamole 3-5 mg/kg/day. In addition, all patients received antioxidants as a combination of vitamin E (800 units) and vitamin C (1000-3000 milligrams) daily. The nephrotic patients had been on a regular protein, non added salt diet and the patients in chronic renal failure group; in addition to the general supportive treatment such as correction of electrolyte and acid base imbalance, had been placed on a low protein, low cholesterol diet and adequate hydration.

## STATISTICAL ANALYSIS

Values in text and tables are expressed as mean  $\pm$  SEM. Non parametric Mann-Whitney was used to establish the significance of between group differences. The differences between pre-and post-

treatment values between each treatment group was performed by Student's paired t-test. The difference was statistically significant when the P value was less than 0.05.

## RESULTS

The initial assessment of oxidant revealed an elevated level of plasma MDA in nephrotic patients ( $3.4 \pm 0.3$   $\mu$  molar versus  $2.6 \pm 1$   $\mu$  molar of controls) as well as in patients with chronic renal failure ( $3.2 \pm 0.6$   $\mu$  molar). The initial level of erythrocyte MDA in both nephrotic ( $11.5 \pm 2$  n mol/L versus  $7.6 \pm 0.9$  n mol/L of control) and chronic renal failure patients ( $10.8 \pm 1$  n mol/L) were also elevated as depicted in Table 1. In respect to the antioxidant study, there was a significant depletion in GSH concentration in nephrotic ( $6.8 \pm 1$   $\mu$  mol/g Hb versus  $9 \pm 1$   $\mu$  mol/g Hb of control) and in chronic renal failure patients ( $6.3 \pm 1$   $\mu$  mol/g Hb). The concentration of vitamin C was also found to be significantly depleted in nephrotic ( $1 \pm 0.8$  mg/L versus  $5.7 \pm 4$  mg/L of control) and in chronic renal failure patients ( $1 \pm 1$  mg/L). The level of vitamin E in plasma in both nephrotic and chronic renal failure patients were not significantly different from the controls. The level of glutathione peroxidase in nephrosis and chronic renal failure patients were  $0.2 \pm 0.2$  n mol/ $10^6$  cells and  $0.2 \pm 0.18$  n mol/ $10^6$  cells respectively which were not significantly different from the control value of  $0.28 \pm 0.4$  n mol/ $10^6$  cells. The oxidant and antioxidant (OA) ratio in both groups of patients were significantly different from the control (Table 1).

The result of renal function study in the nephrosis group revealed a significant impairment. Of the glomerular function, the initial creatinine clearance (CCr) value was  $44.8 \pm 24$  ml/min/ $1.73$  m<sup>2</sup>. The tubular function revealed a significant elevation of FE Mg ( $7.2 \pm 2\%$  versus  $2.2\%$  of control). In the chronic renal failure (CRF) patients, the mean CCr was  $17 \pm 10$  ml/min/ $1.73$  m<sup>2</sup> and the FE Mg was  $13 \pm 6.3\%$ . The intrarenal hemodynamic study revealed a significant reduction in renal plasma flow (RPF)  $219 \pm 84$  ml/min/ $1.73$  m<sup>2</sup> (normal  $600$  ml/min/ $1.73$  m<sup>2</sup>), a low peritubular capillary flow (PTCF)  $167 \pm 67$  ml/min/ $1.73$  m<sup>2</sup> (normal  $480$  ml/min/ $1.73$  m<sup>2</sup>), an elevated efferent arteriolar resistance (RE)  $19442 \pm 5206$  dyne.s.cm<sup>-5</sup> (normal  $3000$  dyne.s.cm<sup>-5</sup>) and an elevated intraglomerular hydrostatic pressure (PG)  $56 \pm 1$  mm Hg versus  $53$  mm Hg of control.

Following the therapy, there had been a significant improvement in oxidant and antioxidant status. The plasma and erythrocyte MDA declined to normal level whereas there had been a steady increase in the concentration of GSH, vitamin C and E as depicted in Table 2. In accordance with this improvement in antioxidant status, there was also a significant improvement in renal function. The creatinine clearance in nephrosis increased to  $60 \pm 34$  ml/min/ $1.73$  m<sup>2</sup> whereas the FE Mg declined to  $5.7 \pm 3\%$  (Table 3). In the CRF patients, the CCr rose to  $23 \pm 12$  ml/min/ $1.73$  m<sup>2</sup> and the FE Mg declined to  $11.4 \pm 6\%$ . The intrarenal hemodynamic study showed a significant

improvement in RPF ( $391 \pm 133$  ml/min/ $1.73$  m<sup>2</sup>), PTCF ( $314 \pm 120$  ml/min/ $1.73$  m<sup>2</sup>), a reduction in RE ( $3918 \pm 2040$  dyne.s.cm<sup>-5</sup>) and PG ( $51 \pm 0.8$  mm Hg).

## DISCUSSION

Reactive oxygen species are implicated in cell signaling, gene transcription, mitosis, apoptosis and vasoconstriction(20,21). The cellular sources of reactive oxygen species are multiple namely NADPH oxidase, lipoxygenases, cyclooxygenase from plasma membrane, electron transport system from mitochondria, xanthine oxidase, hemoglobin, transition metals ( $\text{Fe}^{2+/3+}$ ,  $\text{Cu}^{1+/2+}$ ) from cytosol and cytochrome P-450 from endoplasmic reticulum(22). Increased cellular metabolism with enhanced production of reactive oxygen species have been delineated in a variety of glomerulonephropathies and renal failure(23,24). This study indicates that both increased reactive oxygen species and decreased antioxidant defense have been substantiated in our renal patients. Increased plasma MDA and erythrocyte MDA in conjunction with a depleted plasma vitamin C and a reverse ratio of oxidant and antioxidant imply that there is an oxidant/antioxidant imbalanced state. Similar observation have also been reported(23,24,25). In excess, reactive oxygen species and their byproducts are capable of causing oxidative damage and cytotoxicity to cells. This results in increased oxidized LDL, advanced glycation end products of carbohydrates, fat and protein(26). In the presence of antioxidant imbalance, the defective antioxidant would allow the excessively generated reactive oxygen species to induce a sustained oxidative damage to cells in particular the endothelial cells which is optimally situated at the interface between the circulating blood and the vessel wall to serve as a sensor and transducer of signals within the circulatory microenvironment. The oxidant and antioxidant imbalance observed in this study is likely to explain the in vitro increased endothelial cell cytotoxicity induced by sera of nephrotic patients(5). Increased oxidative stress to the glomerular endothelial cell would induce dysfunctioning of the endothelial cell and in excessive amount incriminate in endothelial cell death. In response to such oxidative injury, the endothelial cell would increase productions of vasoconstrictive substances namely angiotensin II, endothelin and thromboxaneA<sub>2</sub> whereas the production of endothelium dependent vasodilator such as nitric oxide is defective as well as being neutralized by the excessive amount of reactive oxygen species. Such a provasoconstrictive state would induce a hemodynamic maladjustment with a predominant vasoconstriction at the efferent arteriole. The preponderant vasoconstriction at the efferent arteriole not only increases the intraglomerular hydrostatic pressure but also exaggeratedly reduces the peritubular capillary flow which supplies the tubulointerstitial compartment. The hemodynamic study indicates that there is indeed an increase in intraglomerular hydrostatic pressure to  $56 \pm 1$  mm Hg (normal  $\leq 53$  mm Hg) implicating an intraglomerular hypertension. The presence of intraglomerular hypertension in conjunction with the reduction in renal plasma flow (mean  $219 \pm 84$  ml/min/ $1.73$  m<sup>2</sup>) and with the hemorheologic alteration secondary to the additive effect of oxidative stress to the endothelial cell inducing vascular inflammatory gene

expression such as vascular adhesion molecule, mononuclear cell infiltration and procoagulant surface expression; would culminate in the injury to the glomerular cell inducing glomerulosclerosis(27-30).

The reduction in peritubular capillary flow secondary to the hemodynamic maladjustment at the efferent arteriole exerts a significant hemodynamic impact upon the tubulointerstitial structure. It is of notion that a simulated ischemia in flow-adapted endothelial cells leads to generation of reactive species and cell signaling through the NADPH oxidase pathway. This is followed by an increased production of nuclear factor-kappa B which then upregulates the inflammatory gene expressions namely cytokines, growth factors and adhesion molecules(27,28). A sustained reduction in peritubular capillary flow in conjunction with the oxidative stress would therefore, induce an ischemic injury to the tubulointerstitial structure and the development of tubulointerstitial fibrosis. In this regard, increased production of nuclear factor-kappa B was detected in nephrosis associated with focal glomerulosclerosis(31) and increased chemokine expression was also demonstrated in puromycin aminonucleoside nephrosis(32). In this regard, it has recently been demonstrated that there is an inverse correlation between the peritubular capillary flow and the incidence of tubulointerstitial fibrosis(4). That the progressive reduction in peritubular capillary flow as the disease severity progresses inversely increases the magnitude of tubulointerstitial fibrosis. In addition, we have recently demonstrated that there is also a correlation between the renal perfusion and FE Mg(33).

The preceding information renders a supportive view that the oxidative stress and antioxidant defect is likely to be responsible for the endothelial cell cytotoxicity and a spontaneous endothelial cell dysfunction by which it induces a progressive reduction in renal perfusion as the disease severity progresses. In accordance with the therapeutic strategy, a correction of antioxidant defect in conjunction with the administration of vasodilators to correct the hemodynamic maladjustment would likely improve the renal perfusion and prevent the progression of renal disease. Based upon this therapeutically strategic approach, the administration of antioxidants namely vitamin C and vitamin E restores the antioxidant status toward normal. It has been a general concensus that vitamin C is capable of neutralizing super oxide anion, reactive nitrogen species such as peroxynitrite, nitrogen dioxide(34) and also acts as a coantioxidant by regenerating  $\alpha$ -tocopherol (vitamin E) from the  $\alpha$ -tocopherol radical(35-37). Vitamin C has also been shown to regenerate glutathione and B-carotene in vitro from their respective one-electron oxidation product(34,38). Another major property that makes vitamin C such an effective antioxidant is the stability and low reactivity of the ascorbyl radical formed when ascorbate scavenges a reactive oxygen or nitrogen species(39). The impaired endothelium-dependent vasodilation was markedly improved by vitamin C in essential hypertension(40).

In respect to vitamin E, a combined vitamin E and selenium or glutathione deficiency leads to pronounced and progressive oxidative damage to renal structure and function(41-43). Increasing dietary vitamin E level significantly attenuates renal oxidative damage in the puromycin nephrotoxicity model of FSGS in the rat(44,45). Therefore, both vitamins C and E administration would assist in neutralizing the reactive oxygen species and thereby minimizing the tissue damage by oxidative stress. Such an event would spare the vasodilating status of nitric oxide (NO). Increased available NO would exert a cellular protection to the nephronal structure as well as to the glomerular endothelial cell. A decreased endothelial cell cytotoxicity was demonstrated following the therapeutic administration of antioxidants and vasodilators.

In respect to the renal function, the therapeutic regimen reduced the renal arteriolar resistance. The relaxation of efferent arteriole not only reduced the intraglomerular hydrostatic pressure (PG  $51 \pm 0.8$  mm Hg), but also enhanced the peritubular capillary flow. The peritubular capillary flow increased from  $167 \pm 67$  ml/min/1.73 m<sup>2</sup> to  $314 \pm 120$  ml/min/1.73 m<sup>2</sup> following treatment. The improvement in renal perfusion correlated with the glomerular function as well as the tubular function. The creatinine clearance in nephrosis increased from  $44.8 \pm 24$  ml/min/1.73 m<sup>2</sup> to  $60.6 \pm 34$  ml/min/1.73 m<sup>2</sup>, the glomerular filtration rate increased from  $52 \pm 21$  ml/min/1.73 m<sup>2</sup> to  $76 \pm 22$  ml/min/1.73 m<sup>2</sup> and the FE Mg significantly reduced from  $7 \pm 2\%$  to  $5.7 \pm 3\%$  following treatment,  $p < .05$ . In chronic renal failure, the CCr rose from  $17$  ml/min/1.73 m<sup>2</sup> to  $23 \pm 12$  ml/min/1.73 m<sup>2</sup>.

Thus the preceding information renders a supportive view that the oxidant and antioxidant imbalance is likely to induce the glomerular endothelial dysfunction with subsequent hemodynamic maladjustment by which the correction of such disorders by antioxidant therapy and vasodilators can improve the renal function and prevent the renal disease progression.

ศูนย์วิทยทรัพยากร  
จุฬาลงกรณ์มหาวิทยาลัย

Table 1 Oxidant and antioxidant in nephrotic and chronic renal failure patients

	NS	p value	CONTROL	p value	CRF
<b>Oxidant (O)</b>					
P MDA $\mu$ molar	3.4 $\pm$ 0.3	< .05	2.6 $\pm$ 1	< .05	3.2 $\pm$ 0.6
R MDA n mol/L	11.5 $\pm$ 2	< .01	7.6 $\pm$ 0.9	< .01	10.8 $\pm$ 1
<b>Antioxidant(A)</b>					
GSH $\mu$ mol/gHb	6.8 $\pm$ 1	.001	9 $\pm$ 1	.001	6.3 $\pm$ 1
Vit C mg/L	1 $\pm$ 0.8	< .001	5.7 $\pm$ 4	< .001	1 $\pm$ 1
Vit E mM	0.17 $\pm$ 0.2	NS	0.17 $\pm$ 0.1	NS	0.16 $\pm$ 0.1
OA RATIO	1.9 $\pm$ 0.5	< .001	0.7 $\pm$ 0.2	< .001	1.9 $\pm$ 0.5

ศูนย์วิทยทรัพยากร  
จุฬาลงกรณ์มหาวิทยาลัย

Table 2

Initial and post treatment values of oxidant and antioxidant in nephrotic and CRF patients

	Initial	Post treatment	p value
GSH $\mu$ mol/gHb	6.8 $\pm$ 1.5	8.2 $\pm$ 1.7	< .001
Vit C mg/L	1.2 $\pm$ 1.4	4.3 $\pm$ 1.9	< .001
Vit E mM	0.17 $\pm$ 0.1	0.29 $\pm$ 0.1	< .001
P-MDA $\mu$ molar	3.2 $\pm$ 0.9	1.5 $\pm$ 0.9	< .001
R-MDA n mol/L	11.2 $\pm$ 3	5.6 $\pm$ 3	< .001

ศูนย์วิทยุพัชกร  
จุฬาลงกรณ์มหาวิทยาลัย

Table 3

Initial and post treatment values of renal function in nephrosis

	Initial	Post treatment	p value
CCr ml/ min/1.73m <sup>3</sup>	44.8 ± 24	60.6 ± 34	<.05
FE Mg %	7.2 ± 2	5.7 ± 3	<.05



## References

1. Baldwin DS : Chronic glomerulonephritis: non immunologic mechanism of progressive glomerular disease. *Kidney Int* 21:109-120, 1982
2. Futrakul P, Sitprija V, Yenrudi S et al : Glomerular endothelial dysfunction determines disease progression: A hypothesis. *Am J Nephrol* 17:533-540, 1997
3. Bohle A, Mackensen-Haen S, Wehrmann M : Significance of postglomerular capillaries in the pathogenesis of chronic renal failure. *Kidney and Blood Press Res* 19:191-195, 1996
4. Futrakul N, Yenrudi S, Sensirivatana R et al : Peritubular capillary flow determines tubulointerstitial disease in idiopathic nephrotic syndrome. *Ren Fail* 22:329-335, 2000
5. Futrakul N, Panichakul T, Chaisuriya P, Sirisinha S, Futrakul P, Patumraj S : Endothelial cell cytotoxicity induced by nephrotic serum. *Proceeding 2<sup>nd</sup> Congress of the Federation of Immunological Societies of Asia-Oceania, Bangkok. Monduzzi Editore* 2000 pp 27-31
6. Diamond JR, Bonventre JV, Karnovsky MJ : A role for oxygen free radicals in aminonucleoside nephrosis. *Kidney Int* 29:478-483, 1986
7. Wardle EN : Oxidative processes in glomerulonephritides: Additional facts. *Nephron* 85:103-106, 2000
8. Shah SV : Role of reactive oxygen metabolites in experimental glomerular disease. *Kidney Int* 35:1093-1106, 1989
9. Baliga R, Veda N, Shah SV : Oxidant mechanisms in glomerular disease; in Gonich HC (ed) : *Current Nephrology*. St Louis, Mosby 1997, chap 4, pp 135-151
10. Kahsem A, Endoh M, Nomoto Y, Sakai N, Nakazawa H : FC $\alpha$ R expression on polymorphonuclear leukocytes and super oxide generation in IgA nephropathy. *Kidney Int* 45:868-875, 1994
11. Clarkson MR, McGinty A, Godson C, Brady HR : Leukocyte recruitment and vascular tone in glomerulonephritis. *Nephrol Dial Transplant* 13:3043-3051, 1998
12. Marshall JP, Warso AM, Lands EMW : Selective microdetermination of lipid hydroperoxide. *Anal Biochem* 145:192-199, 1985
13. Beutler E, Derron O, Kelly MB : Improved method for the determination of blood glutathione. *J Lab Clin Med* 61:882-888, 1963
14. Cevat IT, Tuli A, Yuregir TG : Evaluation of reference values for erythrocyte glutathione. *Clin Chem Acta* 256:189-196, 1996
15. Liu ZT, Chin N, Kiser DM, Bigler NW : Specific spectrophotometry of ascorbic acid in serum or plasma by use of ascorbate oxidase. *Clin Chem* 28:2225-2228, 1982
16. Motchnik PM, Frei B, Ames BN : Measurement of antioxidants in human blood plasma. *Methods Enzymol* 234:269-279, 1994
17. de Cavanagh EMV, Leon Ferder MS, Larrasquedo F et al : Higher levels of antioxidant defenses in enalapril-treated versus non-enalapril-treated hemodialysis patients. *Am J Kidney Dis* 34:445-455, 1999

18. Futrakul P, Poshyachinda M, Futrakul N et al : Intrarenal hemodynamic alteration and tubular functions in nephrotic syndrome associated with focal segmental glomerulosclerosis (FSGS): A pathogenetic and therapeutic implication. In Andreucci VE, Dal Canton A (eds), *Current Therapy in Nephrology*. Wichtig Editore, Milano 1993; 107-114
19. Futrakul P, Futrakul N, Sitprija V : Enhanced renal perfusion improves function in severe nephrosis with focal segmental glomerulosclerosis. *Nephrology* 1:51-57, 1995
20. McIntyre M, Bohr DF, Dominiczak AF : Endothelial function in hypertension. *Hypertens* 34:539-545, 1999
21. Kojima G, Hanison D : Interactions between NO and reactive oxygen species; pathophysiologic importance in atherosclerosis, hypertension, diabetes and heart failure. *Cardiovasc Res* 43:562-571, 1999
22. Kunsch C, Medford RM : Oxidative stress as a regulator of gene expression in the vasculators. *Circ Res* 85:753-766, 1999
23. Hasoelwander D, Young IS : Oxidative stress in chronic renal failure. *Free Rad Res* 29:1-11, 1998
24. Galli F, Canestrari F, Bellomo G : Pathophysiology of the oxidative stress and its implication in uremia and dialysis. *Contrib Nephrol* 127:1-31, 1999
25. Becker BN, Himmelfarb J, Henrich WL, Hakim RM : Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. *J Am Soc Nephrol* 8:475-486, 1997
26. Kitiyakara C, Gonin J, Massy Z, Wilcox CS : Non-traditional cardiovascular disease risk factors in end-stage renal disease: oxidative stress and hyperhomocysteinemia. *Curr Opin Nephrol Hypertens* 9:477-487, 2000
27. Guijarro C, Egido J : Transcription factor-kappa B and renal disease. *Kidney Int* 59:415-424, 2001
28. Wei Z, Costa K, Al-Medhi AB, Dodia C, Muzykantor V, Fisher AB : Simulated ischemia in flow-adapted endothelial cells leads to generation of reactive oxygen species and cell signaling. *Circ Res* 85:682-689, 1999
29. Okada H, Woodcock-Mitchell J, Mitchell J et al : Induction of plasminogen activator inhibitor type 1 and type 1 collagen expression in rat cardiac microvascular endothelial cells by interleukin-1 and its dependence on oxygen-centered free radicals. *Circulation* 97:2175-2182, 1998
30. Futrakul P, Poshyachinda M, Mitrakul C : Focal sclerosing glomerulonephritis: A kinetic evaluation of hemostasis and the effect of anticoagulant therapy : A controlled study. *Clin Nephrol* 10:180-186, 1978
31. Schachter AD, Strom TB : Post-transplant recurrent FSGS: molecular insights and future directions. *Nephron* 82:300-305, 1999
32. Ou ZL, Natai Y, Natori Y : Transient and sequential expression of chemokine in RNA in glomeruli in puromycin aminonucleoside nephrosis. *Nephron* 85:254-257, 2000

33. Futrakul N, Yenrudi S, Futrakul P et al : Peritubular capillary flow and tubular function in idiopathic nephritic syndrome. *Nephron* 85:181-182, 2000
34. Halliwell B : Vitamin C : antioxidant or pro-oxidant in vivo. *Free Radic Res* 25: 439-454, 1996
35. Packer L : Vitamin C and redox cycling antioxidants. In: Packer L, Fuchs I (eds). *Vitamin C in health and disease*. New York, Marcel Dekker Inc, 1997 pp 95-121
36. Bowry VW, Mohr D, Cleary J, Stocker R : Prevention of tocopherol-mediated peroxidation in ubiquinol-10-free human low density lipoprotein. *J Biol Chem* 270: 5756-5763, 1995
37. Carr AC, Frei B : Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. *Am J Clin Nutr* 69:1086-1107, 1999
38. Edge R, Truscott TG : Prooxidant and antioxidant reaction mechanisms of carotene and radical interactions with vitamins E and C. *Nutrition* 13:992-994, 1997
39. Tsao CS : An overview of ascorbic acid and chemistry and biochemistry. In: Packer L, Fuchs J (eds). *Vitamin C in health and disease*. New York, Marcel Dekker Inc, 1997 pp 25-58
40. Taddei S, Viridis A, Ghiadoni L, Magagna A, Salvetti A : Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. *Circulation* 97:2222-2229, 1998
41. Nath KA, Salahudeen AK : Induction of renal growth and injury in the intact rat kidney by dietary deficiency of antioxidants. *J Clin Invest* 86:1179-1192, 1990
42. Hagiwara K, Naito K, Kurokawa Y et al : Kidney injury induced by lipid peroxide produced by vitamin E deficiency and GSH depletion in rats. *J Nutr Sci Vita Minol* 37:99-107, 1991
43. Sadava D, Luo PW, Casper J : Induction of renal damage in rats by a diet deficient in antioxidants. *Nutr Res* 16:1607-1612, 1996
44. Lee HS, Jeong JY, Kim BC et al : Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. *Kidney Int* 51:1151-1159, 1997
45. Trachtman H, Schwob N, Maesaka J et al : Dietary vitamin E supplementation ameliorates renal injury in chronic puromycin aminonucleoside nephropathy. *J Am Soc Nephrol* 5:1811-1819, 1995